MedPath

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Phase 3
Completed
Conditions
Major Depressive Disorder
Interventions
Drug: Placebo
Registration Number
NCT03738215
Lead Sponsor
AbbVie
Brief Summary

The objective of this study is to evaluate the efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with MDD who have had an inadequate response to antidepressants alone.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
759
Inclusion Criteria
  • Written informed consent has been obtained.
  • Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information [US sites] and written Data Protection consent [EU sites]).
  • Patient must be an outpatient at the time of Visit 1 (Screening).
  • Patient meets the DSM-5 criteria for MDD based on SCID-5, with a current major depressive episode of at least 8 weeks and not exceeding 24 months in duration at Visit 1/Screening. A diagnosis of MDD with psychotic features will be acceptable.
  • Diagnosis of MDD confirmed through a formal adjudication process.
  • Patient demonstrates ability to follow study instructions and likely to complete all required visits.
  • Patient must have an inadequate response, as measured by the modified ATRQ, to 1 to 3 antidepressants administered during the current episode at an adequate dose (as per package insert) and for at least 6 weeks duration, with at least one dose escalation during the current depressive episode.
  • Only one antidepressant (of sufficient dose per package insert and taken for at least 6 weeks) will be allowed at randomization and patients must agree to continue taking the same ADT dosing regimen through completion of Visit 6/ET. Patients who are taking more than one antidepressant at Screening, regardless of the indication, will need to discontinue all other antidepressants prior to Visit 2 (Baseline).
  • Male and female patients must agree to use a medically acceptable and highly effective method of birth control during the course of the entire study.
  • Women of childbearing potential (only) must have a negative serum β-human chorionic gonadotropin pregnancy test prior to Visit 2.
Exclusion Criteria
  • Diagnosis of any current psychiatric diagnosis other than MDD (including those with current intellectual development disability) with the exception of specific phobias.
  • Patient has a history of intolerance or hypersensitivity to cariprazine or other drugs of the same class or to rescue medications.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placebo + ADTPlaceboDuring the double blind treatment period (6 weeks), participants will take 1 capsule of placebo, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
Cariprazine 1.5 mg/Day + ADTCariprazineDuring the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline).
Cariprazine 3 mg/Day + ADTCariprazineDuring the double blind treatment period (6 weeks), participants will take 1 capsule of cariprazine 1.5mg, orally, per day for two weeks in addition to their ongoing ADT (Same antidepressant and dose of ADT they were on at the Visit 2 baseline). They will then titrate to Cariprazine 3 mg, orally per day, in addition to their ADT starting at Visit 4 (Week 2).
Primary Outcome Measures
NameTimeMethod
Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale)Baseline and Week 6

The MADRS is a 10-item, clinician-rated scale that evaluates the patient's depressive symptomatology during the past week. Patients are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline to Week 6 in the Clinical Global Impressions-Severity (CGI-S) ScoreBaseline and Week 6

The CGI-S is a clinician-rated scale used to rate the severity of the participant's current state of mental illness compared with MDD population. The participant was rated on a scale from 1 to 7, where 1=normal, not at all ill and 7=among the most extremely ill participants. Higher scores indicate worsening of mental illness. A negative change from Baseline indicates improvement. MMRM was used for analyses. mITT Population included all randomized participants who had ≥1 postbaseline assessment of the MADRS total score. Number of subjects analyzed are the number of participants with data available for analyses.

Trial Locations

Locations (125)

Lehigh Center for Clinical Research /ID# 236702

🇺🇸

Allentown, Pennsylvania, United States

Hassman Research Institute /ID# 237501

🇺🇸

Berlin, New Jersey, United States

Psych Atlanta /ID# 235835

🇺🇸

Marietta, Georgia, United States

Pharmasite Research, Inc. /ID# 237395

🇺🇸

Baltimore, Maryland, United States

West Tallinn Central Hospital /ID# 237078

🇪🇪

Tallinn, Estonia

KNP Kyiv City Psychoneurological Hospital /ID# 235093

🇺🇦

Kyiv, Ukraine

Vinnytsia Regional Psycho-Neurological Hospital /ID# 235178

🇺🇦

Vinnytsia, Ukraine

Vinnytsia Regional Psycho-Neurological Hospital /ID# 235179

🇺🇦

Vinnytsia, Ukraine

Sharp Mesa Vista Hospital /ID# 235797

🇺🇸

San Diego, California, United States

Altea Research Institute /ID# 236726

🇺🇸

Las Vegas, Nevada, United States

CTI Clinical Trial and Consulting /ID# 236271

🇺🇸

Cincinnati, Ohio, United States

Red Oak Psychiatry Associates /ID# 236600

🇺🇸

Houston, Texas, United States

Alea Research /ID# 234789

🇺🇸

Phoenix, Arizona, United States

IPS Research Company /ID# 237671

🇺🇸

Oklahoma City, Oklahoma, United States

Axiom Research /ID# 236268

🇺🇸

Colton, California, United States

ATP Clinical Research, Inc /ID# 236619

🇺🇸

Costa Mesa, California, United States

Woodland Research Northwest, LLC /ID# 236641

🇺🇸

Rogers, Arkansas, United States

Earle Research /ID# 236661

🇺🇸

Friendswood, Texas, United States

CBH Health LLC /ID# 234536

🇺🇸

Gaithersburg, Maryland, United States

Coastal Carolina Research Center /ID# 235909

🇺🇸

North Charleston, South Carolina, United States

Clinic of Psychiatry /ID# 235878

🇧🇬

Plovdiv, Bulgaria

FutureSearch Trials of Dallas, LP /ID# 236275

🇺🇸

Dallas, Texas, United States

Psychiatric Consultants PC /ID# 235839

🇺🇸

Franklin, Tennessee, United States

State Psychiatry Hospital-Kardzhali; Third Male Department /ID# 234625

🇧🇬

Kardzhali, Bulgaria

Pillar Clinical Research LLC /ID# 234465

🇺🇸

Richardson, Texas, United States

Medical Center Sveti Naum EOOD /ID# 236069

🇧🇬

Sofia, Bulgaria

UMHAT Alexandrovska EAD /ID# 237834

🇧🇬

Sofiya, Sofia, Bulgaria

MHAT Dr. Hristo Stambolski EOOD; Hospital Pharmacy /ID# 234773

🇧🇬

Kazanlak, Bulgaria

Neuropsychiatric Associates LLC/DBA Woodstock Research Center /ID# 236087

🇺🇸

Woodstock, Vermont, United States

Mental health Centre-Ruse EOOD /ID# 234775

🇧🇬

Ruse, Bulgaria

Core Clinical Research /ID# 236405

🇺🇸

Everett, Washington, United States

Medical Center Mentalcare OOD /ID# 234934

🇧🇬

Plovdiv, Bulgaria

Medical Centre - VAS OOD /ID# 235719

🇧🇬

Targovishte, Bulgaria

Diagnostic consultative center Mladost M /ID# 236253

🇧🇬

Varna, Bulgaria

Mental Health Center - Veliko Tarnovo EOOD Veliko Tarnovo /ID# 236078

🇧🇬

Veliko Tarnovo, Bulgaria

Diagnostic consultative center Mladost M /ID# 236254

🇧🇬

Varna, Bulgaria

Obudai Egeszsegugyi Centrum Kft. /ID# 237495

🇭🇺

Budapest, Pest, Hungary

Klinikum Chemnitz gGmbH /ID# 237758

🇩🇪

Chemnitz, Germany

Bugat Pal Korhaz /ID# 238145

🇭🇺

Gyöngyös, Heves, Hungary

BAG Prof. Dr. Kunte / Dr. sc. med. A. Schulze /ID# 235970

🇩🇪

Berlin, Germany

Szent Borbala Korhaz /ID# 238293

🇭🇺

Tatabanya, Komarom-Esztergom, Hungary

Semmelweis Egyetem /ID# 237096

🇭🇺

Budapest, Hungary

Cherkasy regional psychiatric hospital of the CRC /ID# 234513

🇺🇦

Smila, Cherkaska Oblast, Ukraine

SI Institution Neurology Psychiatry and Narcology NAMS of Ukraine /ID# 236338

🇺🇦

Kharkiv, Kharkivska Oblast, Ukraine

SI Institution Neurology Psychiatry and Narcology NAMS of Ukraine /ID# 236340

🇺🇦

Kharkiv, Kharkivska Oblast, Ukraine

Kherson Regional Psychiatric Institution for Psychiatric Care /ID# 234509

🇺🇦

Stepanivka Village, Khersonska Oblast, Ukraine

Kyiv Railway Clinical Hosp No.2 /ID# 237405

🇺🇦

Kyiv, Ukraine

Knowle House Surgery /ID# 235025

🇬🇧

Plymouth, Devon, United Kingdom

MAC Clinical Research /ID# 235938

🇬🇧

Blackpool, United Kingdom

Oregon Center for Clinical Investigations, Inc. - Portland /ID# 236649

🇺🇸

Portland, Oregon, United States

Private Practice - Dr. Thomsen /ID# 235713

🇩🇪

Berlin, Germany

MVZ LIO Berlin /ID# 235711

🇩🇪

Berlin, Germany

Houston Clinical Trials /ID# 234442

🇺🇸

Bellaire, Texas, United States

Varoskapu Rendelo - Processus Kft. /ID# 235170

🇭🇺

Budapest, Hungary

Precise Research Centers /ID# 236598

🇺🇸

Flowood, Mississippi, United States

Atria Clinical Research /ID# 237988

🇺🇸

Little Rock, Arkansas, United States

Advanced Research Center /ID# 237957

🇺🇸

Anaheim, California, United States

California Pharmaceutical Research Institute /ID# 236732

🇺🇸

Anaheim, California, United States

Collaborative Neuroscience Research - Orange County /ID# 237639

🇺🇸

Garden Grove, California, United States

ProScience Research Group /ID# 236442

🇺🇸

Culver City, California, United States

Synergy San Diego /ID# 236654

🇺🇸

Lemon Grove, California, United States

Irvine Clinical Research /ID# 237409

🇺🇸

Irvine, California, United States

Omega Clinical Trials LLC /ID# 238168

🇺🇸

La Habra, California, United States

Olympian Clinical Research /ID# 237417

🇺🇸

Clearwater, Florida, United States

Viking Clinical Research /ID# 236614

🇺🇸

Temecula, California, United States

Space Coast Neuropsychiatric Research Institute /ID# 235765

🇺🇸

Palm Bay, Florida, United States

Anderson Clinical Research /ID# 236627

🇺🇸

Redlands, California, United States

Reliable Clinical Research /ID# 234786

🇺🇸

Hialeah, Florida, United States

MD Clinical

🇺🇸

Hallandale Beach, Florida, United States

CNS Healthcare - Jacksonville /ID# 238241

🇺🇸

Jacksonville, Florida, United States

Institute for Advanced Medical Research /ID# 236672

🇺🇸

Alpharetta, Georgia, United States

Capstone Clinical Research /ID# 236546

🇺🇸

Libertyville, Illinois, United States

iResearch Atlanta, LLC /ID# 237389

🇺🇸

Decatur, Georgia, United States

Pillar Clinical Research /ID# 235702

🇺🇸

Lincolnwood, Illinois, United States

Lake Charles Clinical Trials /ID# 237723

🇺🇸

Lake Charles, Louisiana, United States

NeuroPsychiatric Research Practice & Associate LTD /ID# 234636

🇺🇸

Winfield, Illinois, United States

J. Gary Booker MD APMC /ID# 234514

🇺🇸

Shreveport, Louisiana, United States

Millennium Psychiatric Associates LLC /ID# 235989

🇺🇸

Saint Louis, Missouri, United States

Alivation Research /ID# 236583

🇺🇸

Lincoln, Nebraska, United States

Integrative Clinical Trials /ID# 236656

🇺🇸

Brooklyn, New York, United States

Manhattan Behavioral Medicine PLLC /ID# 236314

🇺🇸

New York, New York, United States

Richard Weisler MD, PA & Assoc /ID# 237424

🇺🇸

Raleigh, North Carolina, United States

Quest Therapeutics of Avon Lake /ID# 236282

🇺🇸

Avon Lake, Ohio, United States

Finger Lakes Clinical Research /ID# 236578

🇺🇸

Rochester, New York, United States

The Ohio State University Department of Psychiatry /ID# 234583

🇺🇸

Columbus, Ohio, United States

New Hope Clinical Research Inc. /ID# 234557

🇺🇸

Charlotte, North Carolina, United States

CincyScience /ID# 236391

🇺🇸

West Chester, Ohio, United States

Sooner Clinical Research /ID# 236346

🇺🇸

Oklahoma City, Oklahoma, United States

Clinical Neuroscience Solutions - Memphis /ID# 237476

🇺🇸

Memphis, Tennessee, United States

AIM Trials /ID# 236369

🇺🇸

Plano, Texas, United States

Northwest Clinical Research Center /ID# 237584

🇺🇸

Bellevue, Washington, United States

UMHAT Dr Georgi Stranski EAD /ID# 237828

🇧🇬

Pleven, Bulgaria

Medical Center Hera EOOD /ID# 235859

🇧🇬

Sofia, Bulgaria

Medical complex Doverie /ID# 238307

🇧🇬

Sofia, Bulgaria

Mental Health Center - Vratsa EOOD Hospital Pharmacy /ID# 235960

🇧🇬

Vratsa, Bulgaria

OU Jaanson and Laane /ID# 234985

🇪🇪

Tartu, Estonia

Marienthali Kliinik /ID# 235677

🇪🇪

Tallinn, Estonia

Universitaetsklinikum Frankfurt /ID# 237292

🇩🇪

Frankfurt am Main, Hessen, Germany

Emovis GmbH /ID# 235010

🇩🇪

Berlin, Germany

PsychoTech Kft. /ID# 235008

🇭🇺

Pecs, Baranya, Hungary

Studienzentrum Nord-West /ID# 236357

🇩🇪

Westerstede, Germany

Bacs-Kiskun Megyei Oktatokorhaz Szent-Kereszt Korhaz /ID# 235974

🇭🇺

Kalocsa, Bacs-Kiskun, Hungary

Clinexpert Kft /ID# 237266

🇭🇺

Budapest, Hungary

Jozsefvarosi Szent Kozma Egeszsegugyi Kozpont /ID# 235095

🇭🇺

Budapest, Hungary

Nyiro Gyula Orszagos Pszichiatriai és Addiktologiai Intezet /ID# 235912

🇭🇺

Budapest, Hungary

KNP Zakarpatskyi Regional MC of Mental Health and Medicine of Dependencies /ID# 234499

🇺🇦

Uzhgorod, Zakarpatska Oblast, Ukraine

MAC Clinical Research /ID# 235945

🇬🇧

Blackpool, United Kingdom

MAC Clinical Research /ID# 235941

🇬🇧

Blackpool, United Kingdom

MAC Clinical Research /ID# 239078

🇬🇧

Blackpool, United Kingdom

MAC Clinical Research-Manchester /ID# 235940

🇬🇧

Manchester, United Kingdom

Austin Clinical Trial Partners /ID# 236551

🇺🇸

Austin, Texas, United States

SI Institution Neurology Psychiatry and Narcology NAMS of Ukraine /ID# 236336

🇺🇦

Kharkiv, Kharkivska Oblast, Ukraine

Tartu University Hospital /ID# 237079

🇪🇪

Tartu Linn, Tartumaa, Estonia

Geikivka multidisciplinary hospital for psychiatric care /ID# 234498

🇺🇦

Kryvbas Village, Dnipropetrovska Oblast, Ukraine

CNE of LOR Lviv Regional Clinical Psychiatric Hospital /ID# 236270

🇺🇦

Lviv, Ukraine

Odesa regional psychiatric hospital 2 of the ORC /ID# 234505

🇺🇦

Oleksandrivka Village, Odeska Oblast, Ukraine

MNCE Odesa Regional Medical Center for Mental Health /ID# 235723

🇺🇦

Odesa, Ukraine

Ternopil University Hospital /ID# 236819

🇺🇦

Ternopil, Ukraine

St. Peter's Hospital Surrey and Borders Partnership NHS FT /ID# 235725

🇬🇧

Chertsey, Surrey, United Kingdom

University of South Florida /ID# 234386

🇺🇸

Tampa, Florida, United States

Michigan Clinical Research Institute /ID# 234792

🇺🇸

Ann Arbor, Michigan, United States

BioBehavioral Research of Austin /ID# 236477

🇺🇸

Austin, Texas, United States

NeuroBehavioral Medicine Group /ID# 236671

🇺🇸

Bloomfield Hills, Michigan, United States

KNP Prykarpatskyi Regional Clinical Centre of Mental Health /ID# 234999

🇺🇦

Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine

Arztpraxis Dr Kirsten Hahn /ID# 235958

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath